Adam Kibel, MD

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Myovant
    Mitigation strategy: 
    Divest
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Exlexis
    Mitigation strategy: 
    Divest
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Insight Diagnositics
    Mitigation strategy: 
    Divest
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    AstraZeneca
    Mitigation strategy: 
    Divest
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Bayer
    Mitigation strategy: 
    Divest
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    General Electric
    Mitigation strategy: 
    Divest
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Other (Oncology)
    Ineligible company: 
    advantagene
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Specialty Not Specified)
    Ineligible company: 
    Merck
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Other (Specialty Not Specified)
    Ineligible company: 
    Bristol-Myers Squibb
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Specialty Not Specified)
    Ineligible company: 
    Janssen
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    09/20/2022

Pages

Return to 2022 AUA Annual Meeting Highlights: Prostate Cancer